Profile for Incyte Corporation (INCY)

$ 103.02   2.46 (+2.45%) Volume: 1.69m 4:00 PM EDT Jul 14, 2020
After Hours:  $ 103.02 0.00 (0.00%) Volume: 92.88k 7:55 PM EDT Jul 14, 2020
Business Description:
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.
Address: 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Telephone: +1 302 498-6700 Website:
Facsimile: N/A Email: [email protected]
CEO: Herve Hoppenot
Employees: 1,456 Market Cap: 22.39b
Issue Type: CS
Auditor: Ernst & Young LLP
Last Audit: Unqualified Opinion with Explanation
Indices: N/A
Industry Classifications
Sector: Healthcare CIK: 879169
Industry: Biotechnology
Sub-Industry:    Biotechnology
NAICS: Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC: Commercial Physical And Biological Research (8731)